Browse our anti-F2R (F2R) Antibodies

Human Coagulation Factor II (thrombin) Receptor (F2R) interaction partners

1. The activation of PAR-1 (show MARK2 Antibodies) on the cell surface of SGC7901 and AGS (show JAG1 Antibodies) cells was significantly reduced after the knockdown of EPCR (show PROCR Antibodies). By contrast, blockade of PAR-1 (show MARK2 Antibodies) reduced the proliferation and migration of gastric cells in vitro

2. Our structural data showed subtle changes in the binding pose between Vorapaxar and F16357. Transmembrane helices 1, 2, 5, and 7 were most significantly affected; most notably a large kink at F279(5.47) in TM helix 5 of the Vorapaxar complex was completely absent in the F16357 complex. The results of this study facilitate the future development of other therapeutic PAR1 (show MARK2 Antibodies) antagonists.

3. Platelets were activated in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients, and such activation was at least partially attributed to the thrombin (show F2 Antibodies)-protease-activated receptors (PARs (show EPRS Antibodies)) pathway.

4. Using protein C-factor VII (show TH Antibodies) chimera demonstrate that APC (show APC Antibodies) light chain amino acid residues outside the EPCR (show PROCR Antibodies)-binding site enable cytoprotective PAR1 (show MARK2 Antibodies) signaling.

5. Study demonstrated that nerve activation by mucosal biopsy supernatants depends on proteases. This is a common feature of quiescent ulcerative colitis and irritable bowel syndrome (IBS) and may relate to some common gastrointestinal symptoms. However, only proteases in IBS supernatants signal through PAR1 (show MARK2 Antibodies).

6. Data show there was no significant correlation of autoantibodies to coagulation factor II thrombin receptor (F2R; protease-activated receptor 1, PAR1) (PAR1-AB) level with , progression-free (PFS) and overall (OS) survival.

7. we found that activation of the protease-activated receptor 1 (PAR1) induced secretion of TSLP (show TSLP Antibodies) by the corneal stromal cells... we proposed that TSLP (show TSLP Antibodies) might function as the link between increased protease activity and inflammatory responses or itch sensation in the

8. PAR-1 (show MARK2 Antibodies) in non-small-cell lung cancer is mainly expressed on cells that constitute the pulmonary tumor microenvironment, including vascular endothelial cells, macrophages and stromal fibroblasts.

9. thrombin (show F2 Antibodies) binding to PAR-1 (show MARK2 Antibodies) receptor activated Gi-protein/c-Src (show SRC Antibodies)/Pyk2 (show PTK2B Antibodies)/EGFR (show EGFR Antibodies)/PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies)/p42/p44 (show PSMC6 Antibodies) MAPK (show MAPK3 Antibodies) cascade, which in turn elicited AP-1 (show FOSB Antibodies) activation and ultimately evoked MMP-9 (show MMP9 Antibodies) expression and cell migration in SK-N-SH cells.

10. this study demonstrates that TGFbeta (show TGFB1 Antibodies) is a positive regulator of PAR-1 (show MARK2 Antibodies) expression in A549 lung adenocarcinoma cells, which in turn increases the sensitivity of these cells to thrombin (show F2 Antibodies) signalling

Mouse (Murine) Coagulation Factor II (thrombin) Receptor (F2R) interaction partners

1. PAR-1 (show MARK2 Antibodies) plays an important role in the development of diabetic nephropathy (DN) and PAR-1 (show MARK2 Antibodies) might therefore be an attractive therapeutic target to pursue in DN.

2. Experimental TCDD-elicited steatohepatitis is associated with coagulation cascade activation and PAR-1 (show MARK2 Antibodies)-driven hepatic inflammation and fibrosis.

3. PAR1 in its inactive unligated state functions as a scaffold for TGFbetaRII to downregulate TGF-beta (show TGFB1 Antibodies) signaling, and thereby promote embryonic stem cell transition to functional endothelial cells.

4. this study shows that poly I:C treated PAR-1 (show MARK2 Antibodies)-/- mice given the thrombin (show F2 Antibodies) inhibitor dabigatran etexilate exhibited less IFNbeta and CXCL10 (show CXCL10 Antibodies) expression in the spleen and plasma

5. Brain water content in the ipsilateral hemisphere and the tumor mass were significantly lower in PAR-1 (show MARK2 Antibodies) KO than WT mice at day 12 after implantation of glioma cells.

6. The results of this study suggested that polarized microglia occur dynamically after ICH (show ACE Antibodies) and that PAR-1 (show MARK2 Antibodies) plays a role in the microglia activation and polarization.

7. In this study, we found upregulation of several hemostasis-related genes, including the thrombin (show F2 Antibodies)-activatable receptor PAR-1 (protease-activated receptor-1), in Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies)-deleted MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells. Similar to the effect of Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies) deletion, PAR-1 (show MARK2 Antibodies) overexpression induced CDKN1A/p21 (show CDKN1A Antibodies) expression and attenuated proliferation in MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells

8. our findings define a detrimental role of thrombin (show F2 Antibodies)-activated PAR-1 (show MARK2 Antibodies) in wound healing in mice with spinal cord injuries.

9. thrombin (show F2 Antibodies)/PAR-1 (show MARK2 Antibodies) interaction regulated MCP-1 (show CPT1B Antibodies), TF, MCSF (show CSF1 Antibodies) and IL-6 (show IL6 Antibodies) production.

10. Thrombin (show F2 Antibodies) upregulates LCN2 (show LCN2 Antibodies) through protease-activated receptor-1 activation and causes brain damage.

Pig (Porcine) Coagulation Factor II (thrombin) Receptor (F2R) interaction partners

1. Thrombin (show F2 Antibodies) stimulates swine smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA (show RHOA Antibodies), and myocardin (show MYOCD Antibodies).

2. Thrombin (show F2 Antibodies) induces a sustained contraction in the normal pulmonary artery, by activating PAR(1) and thereby increasing the sensitivity of the myofilament to Ca(2 (show CA2 Antibodies)+).

Cow (Bovine) Coagulation Factor II (thrombin) Receptor (F2R) interaction partners

1. MMP-1 (show MMP1 Antibodies) promotes VEGFR2 (show KDR Antibodies) expression and proliferation of endothelial cells through stimulation of PAR-1 and activation of NF-kappaB (show NFKB1 Antibodies)

2. PAR1 and PAR2 regulate endothelial NO synthase phosphorylation and activity through G(12/13) and G(q), delineating the signaling pathways by which the proteases act on protease-activated receptors to modulate endothelial functions.